Reporter Nam Hyun-woo Page 1

The Korea Times

Site Map E-paper Subscribe Register LogIn
Site Map E-paper Subscribe Register LogIn

Reporter : Nam Hyun-woo

Sun, January 17, 2021 | 09:43

Doosan Group's successful restructuring is now up to Hyundai Heavy

Doosan Group's efforts to sell its construction equipment unit Doosan Infracore and finish its restructuring program now hinge on Infracore's preferred bidder Hyundai Heavy Industries (HHI) Group, which holds the key to settling a Doosan-investor dispute over Infracore's Chinese body.

Manufacturing | 2021-01-15 17:03

Kia removes 'Motors' from its corporate name

Kia has removed “Motors” from its corporate name as the firm attempts to break away from its traditional manufacturing-driven business model, the company announced, Friday.

Auto | 2021-01-15 17:02

Why treatments unlikely to be 'game changer' in COVID-19 battle

Celltrion has revealed positive Phase 2 clinical trial results for its COVID-19 treatment Regkirona, also known as CT-P59, raising expectations that the firm will get conditional approval for its use here as early as this month. The treatment is anticipated to be a new addition to the arsenal of drugs that can be used to fight the coronavirus in and outside Korea, but experts...

Health & Welfare | 2021-01-15 10:04

Samsung Biologics eyes 'multidimensional expansion' for next decade

John Rim, the new CEO of Samsung Biologics, said the company will pursue multidimensional expansion in the biopharmaceutical industry, ranging from its existing contract development and manufacturing organization (CDMO) business to developing proprietary new drugs.

Health & Welfare | 2021-01-13 23:40

Celltrion's COVID treatment has efficacy in Phase 2 trials

Celltrion said Wednesday that its Regkirona anti-COVID-19 drug, also known as CT-P59, has had its efficacy proven for the treatment of patients with mild to moderate symptoms of the coronavirus disease in global Phase 2 clinical trials. This bodes well for the company to win domestic approval for use of the treatment in Korea.

Health & Welfare | 2021-01-13 21:08

Hyundai Motor will stop developing new diesel engines

Hyundai Motor Group will stop developing new diesel engines, as part of the group's initiative to lower its reliance on internal combustion engines and swiftly transition to electric vehicles (EVs) and hydrogen fuel cell EVs. Although the company will continue assembling diesel vehicles for a while and make improvements to existing engines, the bottom line strategy is to phas...

Auto | 2021-01-13 15:27

Hanmi Pharm seeks FDA approvals of two novel drugs

Hanmi Pharmaceutical said it is expecting the U.S. Food and Drug Administration (FDA) to approve two novel drugs this year, raising expectations over the company's pipeline. The announcement was made during the J.P. Morgan Health Care Conference, Tuesday.

Health & Welfare | 2021-01-12 15:46

Hyundai Avante wins 2021 North American Car of the Year Award

The Hyundai Avante, sold as the Elantra in the U.S., has won the 2021 North American Car of the Year Award, one of the most prestigious automotive accolades in the region, Hyundai Motor and the award's organizer said Tuesday.

Auto | 2021-01-12 14:39

Why Hyundai is contemplating over partnership with Apple

Hyundai Motor gave a rare confirmation that it was in “an early stage talk” with Apple over strategic partnership under which the Korean car manufacturer may assemble the Cupertino-based iPhone designer's forthcoming electric vehicles (EVs), but questions are being raised on the feasibility of the two companies' cooperation.

Auto | 2021-01-11 16:32

Il-Yang Pharm CEO honored for contributions in healthcare

Il-Yang Pharmaceutical CEO Kim Dong-yeon has received the top prize in the healthcare segment of the 6th Korea Awards, for his firm's contribution to developing the leukemia treatment Supect.

Health & Welfare | 2021-01-11 15:28

1 2 3 4 5 6 7 8 9 10

WooriBank

photo news

Second Trump impeachment [PHOTOS]

WooriBank

Code of Ethics

Copyright